Project Details
Description
Of the many immunotherapy approaches under development, the ability to use bispecific antibodies or
chimeric antigen receptors (CARs) to direct T-cells to selectively kill tumor cells has demonstrated significant
early success. Typically, bispecific antibodies or bispecific T-cell engagers (i.e., BiTes) cross-link T-cells by
binding to CD3 and to a target cancer cell surface antigen, usually through a monovalent interaction. An
alternative approach is to genetically engineer a cancer patient’s T-cells to express a single chain antibody
(scFv)-CD3ζ fusion protein that can target the cancer cell surface antigen. After re-introduction into the patient,
CAR-expressing T-cells have been able to selectively eliminate the target cancer cells. While successful, the
genetic engineering of cell surfaces is time consuming and irreversible and the use of BiTes requires
continuous infusion. Furthermore, the resistance to both approaches due to antigen loss has been observed.
Our group has shown that two dihydrofolate reductase molecules (DHFR2) fused to an αCD3 single chain
antibody (scFv) can be engineered to spontaneously self-assemble upon the addition of the chemical
dimerizer, bis-methotrexate (BisMTX), into either highly stable octavalent chemically self-assembled nanorings
(CSANs). CSANs have been prepared with BisMTX containing a third arm, thus enabling it to be conjugated to
oligonucleotides, fluorophores, radiolabels and drugs. Recently, we have prepared αEpCAM/αCD3 CSANs
and αCD133/αCD3-CSANs. The bispecific CSANs rapidly (min) and stably (days) bind to CD3 on T-cell
membranes, thus forming chemically self assembled prosthetic antigen receptor (PAR) T-cells. Upon
incubation of the PAR T-cells with EpCAM+ and/or CD133+ cancer cells, rapid and selective killing of primary
and tumor initiating cancer stem cells (CSC) was observed. We have also demonstrated with an orthotopic
murine cancer model that αEpCAM and αCD133 PAR T-cells are non-toxic and able in combination to
eradicate tumors in vivo. A unique safety feature of our approach is the ability to remove the CSANs from the
T-cells by dosing with the FDA-approved non-toxic antibiotic trimethoprim at clinically relevant concentrations,
thus allowing us to deactivate the cells pharmacologically and reduce cytokine release.
Consequently, as an alternative to current approaches, we determine the generality T-cell induced killing
and eradication of TNBC tumors with αEpCAM/α-CD3-CSANS and αCD133/αCD3-CSANS. In addition, we will
develop a tripspecific αEpCAM/αCD133/αCD3 CSANs that will allow the simultaneous elimination of TNBC
primary tumor cells and CSC. The successful completion of the project milestones should result in the
elucidation of the key features governing a chemical biologically based non-genetic and reversible method for
T-cell targeting, as well as the importance of CD133 on TNBC proliferation. These rules will be applicable to
the clinical development of anti-cancer immunotherapy with greater selectivity, lower toxicity and a reduced
ability for the development of resistance.
Status | Active |
---|---|
Effective start/end date | 3/1/20 → 2/28/25 |
Funding
- National Cancer Institute: $559,057.00
- National Cancer Institute: $544,030.00
- National Cancer Institute: $569,277.00
- National Cancer Institute: $513,423.00
- National Cancer Institute: $559,059.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.